Business Wire

OH-ENOSIX

16.5.2023 15:01:33 CEST | Business Wire | Press release

Share
enosix, Inc. Closes $10 Million Financing with MK Capital to Support Real-Time SAP Integration

enosix, Inc., the leading technology provider of real-time, prebuilt SAP data integration solutions, announced the successful completion of its $10 million growth financing led by MK Capital. enosix will use the proceeds to accelerate the development and expansion of its SAP integration platform, while expanding its support of Salesforce, MuleSoft, and ServiceNow clients.

enosix is the proven, SAP data integration approach that is relied upon by leading global manufacturers including recent customer additions, Prevost, a member of Volvo Group, Tremco Inc., and Carl Zeiss AG. enosix empowers SAP ERP customers with the critical last mile of integration in real-time, boosting digital transformation efforts by eliminating error-prone, latent, swivel-chair data entry between systems. enosix uplevels data accuracy, automation and business agility in areas such as, but not limited to, sales quoting, IT asset management, business supply-chain management, B2B eCommerce, and more, allowing for greater utilization of business and SAP skilled resources. These advantages translate to a superior customer experience and greater revenue growth.

“Over the past 30 years we have performed detailed due diligence on hundreds of technology companies,” noted Mark Koulogeorge of MK Capital.“ We have never had a company score higher on product quality and reliability than enosix. The product’s high performance over millions of transactions differentiates enosix from its competitors.”

Jamie Bedard, CEO of SAPinsider observed,“The enterprise landscape for SAP customers continues to become more complex. The accelerated adoption of cloud-based solutions as a result of the global pandemic has only added to this complexity. enosix’s unique approach to real-time, virtualized SAP integration triggers a huge sigh of relief by the SAP industry and offers a potential safety net for tens of thousands of enterprise SAP ERP customers who are not only behind in their S/4HANA migration projects, but those who are trying to keep up with the business demands of digital transformation but don’t have the time, resources, or skilled SAP talent available to support a major traditional integration project.”

Nick Fera, CEO of enosix noted “The increasing demand for pre-built, real-time, bi-directional access to legacy ERP solutions, especially during these difficult economic times, positions enosix for tremendous growth. Companies are tired of paying millions to systems integrators for bespoke integration solutions that offer only synchronous experience and require long-term maintenance. The ability to ‘have a two-way conversation’ with your legacy ERP solutions is no longer a dream, enosix has delivered a platform to handle complex pricing and quoting and is now better positioned to expand.”

About enosix, Inc

enosix is the standard for real-time, prebuilt SAP ERP integration. enosix provides real-time data virtualization, which enables a more agile and compliant customer experience by reducing error-prone data entry and information delays. enosix seamlessly connects SAP ECC and S/4HANA systems to modern front-end systems such as Saleforce, MuleSoft, ServiceNow to support rapid digital transformation. The enosix platform leverages low or no-code Packaged Integration Processes (PIP) so companies can quickly realize value—in weeks instead of months. enosix' use of data virtualization unlocks data, business processes, authorizations, and user permissions from SAP without recreating them from the front-end; delivering the back-end translation in an easy-to-understand, real-time, and bi-directional integration. For more information, visit www.enosix.com

About MK Capital

MK Capital is an early-stage lead investor in the software and cloud services industries. The firm's partners, who average more than 20 years of venture capital experience, actively partner with entrepreneurial management teams to build leading companies that accelerate the digital transformation of the global economy. MK Capital manages over $400 million in capital and is actively seeking new investment opportunities. For more information, visit www.mkcapital.com .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005351/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release

Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm

Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release

- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno

The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release

New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights

Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 08:00:00 CEST | Press release

From dating apps to financial details, respondents report seeing a wide range of highly personal information on others' screens 56% of people admit to having looked at strangers’ phone screens accidentally, whereas 24% have done so out of curiosity. 57% identify public transport as the most likely place to notice someone else's screen. While 48%* feel confident they can keep their phone activity private when using it in crowded places, another 52%** acknowledge it is easy to see someone’s screen who is next to you in a public place without trying to look. 33% say they have seen personal content on a stranger’s phone in public. Some smartphone users who have looked at a stranger’s phone screen in public ignore and continue what they were doing (28%) or look away immediately (27%), but others (7%) admit to continuing to look discreetly. The new Samsung Galaxy S26 Privacy Display1 limits side-angle viewing of your screen to protect your privacy in any setting. As millions of Europeans2 ge

RevolKa Reimagines Antibody Engineering with "RevoAb®"1.4.2026 06:30:00 CEST | Press release

A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa’s advanced AI Protein Engineering Engine RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye